Clinical Trial

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Study acronym: VANTAGE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Protocol Amendment History 2 changes
notable Trial sites expanded: 127 -> 130 locations 2026-04-03
notable Trial sites expanded: 123 -> 127 locations 2026-04-02
Trial Details
NCT Number NCT05050136
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Primary Biliary Cholangitis, PBC
Enrollment 260 participants
Start Date 2021-09-22
Primary Completion 2027-04 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-14